Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Targeting Human Cancer by a Glycosaminoglycan Binding Malaria Protein

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Integrative Genomic Analyses Reveal an Androgen-Driven Somatic Alteration Landscape in Early-Onset Prostate Cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Systemic Immune Modulation in Gliomas: Prognostic Value of Plasma IL-6, YKL-40, and Genetic Variation in YKL-40

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. ABCB1 single-nucleotide variants and survival in patients with glioblastoma treated with radiotherapy concomitant with temozolomide

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Cell-free DNA in newly diagnosed patients with glioblastoma - a clinical prospective feasibility study

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Camilla L Christensen
  • Nicholas Kwiatkowski
  • Brian J Abraham
  • Julian Carretero
  • Fatima Al-Shahrour
  • Tinghu Zhang
  • Edmond Chipumuro
  • Grit S Herter-Sprie
  • Esra A Akbay
  • Abigail Altabef
  • Jianming Zhang
  • Takeshi Shimamura
  • Marzia Capelletti
  • Jakob B Reibel
  • Jillian D Cavanaugh
  • Peng Gao
  • Yan Liu
  • Signe R Michaelsen
  • Hans S Poulsen
  • Amir R Aref
  • David A Barbie
  • James E Bradner
  • Rani E George
  • Nathanael S Gray
  • Richard A Young
  • Kwok-Kin Wong
View graph of relations

Small cell lung cancer (SCLC) is an aggressive disease with high mortality, and the identification of effective pharmacological strategies to target SCLC biology represents an urgent need. Using a high-throughput cellular screen of a diverse chemical library, we observe that SCLC is sensitive to transcription-targeting drugs, in particular to THZ1, a recently identified covalent inhibitor of cyclin-dependent kinase 7. We find that expression of super-enhancer-associated transcription factor genes, including MYC family proto-oncogenes and neuroendocrine lineage-specific factors, is highly vulnerability to THZ1 treatment. We propose that downregulation of these transcription factors contributes, in part, to SCLC sensitivity to transcriptional inhibitors and that THZ1 represents a prototype drug for tailored SCLC therapy.

Original languageEnglish
JournalCancer Cell
Volume26
Issue number6
Pages (from-to)909-22
Number of pages14
ISSN1535-6108
DOIs
Publication statusPublished - 8 Dec 2014

    Research areas

  • Animals, Antineoplastic Agents, Cell Line, Tumor, Cyclin-Dependent Kinases, Enzyme Inhibitors, Gene Expression Regulation, Neoplastic, High-Throughput Screening Assays, Humans, Lung Neoplasms, Mice, Molecular Sequence Data, Neoplasms, Experimental, Sequence Analysis, DNA, Small Cell Lung Carcinoma, Transcription Factors, Transcription, Genetic, Xenograft Model Antitumor Assays

ID: 44975051